Cellectis reports Phase 1 data for leukemia therapy lasme-cel
Go back to Cellectis reports Phase 1 data for leukemia therapy lasme-cel| (NASDAQ: CLLS) | Delayed: 3.25 -0.05 (1.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.30 | 52 Week High | $37.55 | |||
| Open | $3.32 | 52 Week Low | $16.35 | |||
| Day High | $3.34 | P/E | N/A | |||
| Day Low | $3.22 | EPS | $0.00 | |||
| Volume | 7,130 | |||||
